Business Wire

BOMBERG

15.7.2021 11:14:08 CEST | Business Wire | Press release

Share
BOMBERG Announces World Premiere "BB01 Automatic Cure the BullDog"

True to its rebellious spirit, BOMBERG has launched the first watch ever to incorporate CBD leaves extract: "BB01 Automatic Cure the BullDog ".

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210715005041/en/

BOMBERG connections to CBD are rooted in the relationship nurtured over the years with dogs.

Since the BOMBERG launch in 2012 the bulldogs, Bolt in Mexico and Duke & Paulina in Switzerland, have always been the official brand ambassadors and mascot.

In 2015 BOMBERG partnered with “Barry Foundation ”, the world’s oldest breeder of St. Bernards and in 2020 with the campaign “Take care of me” supported the “Black Jaguar-White Tiger Foundation ”.

After Bolt suffered an episode of stress, BOMBERG got in touch with “Bouledogue Attitude Foundation ”, in Switzerland, that recommended CBD-based food for its natural properties that help relieve anxiety as well as create a stronger nervous system.

Bolt recovered quickly and helps now spreading the word about BB-01 Automatic Cure the BullDog , the world’s first watch ever containing 100% natural CBD with 0% THC.

Treading an unbeaten path away from the roots of traditional lifestyle industry, BOMBERG embraces the free and insurgent spirit of millions of people around the world who dare to be different and to create their own maverick rules.

The new BB01 Automatic Cure the BullDog combines BOMBERG revolutionary, free and adventurous soul with an outstanding concept and a phenomenal design.

The dial features the instantly recognisable CBD indica plant with its seven serrated leaves and a powerful Super-LumiNova that makes the watch always readable.

BB01 Automatic Cure the BullDog presents real CBD indica leaves extract inside the dial and a strap made of authentic hemp, produced by our partner in the United States, following the strictest sustainability and natural production standards.

BB-01 Automatic Cure the BullDog is the ultimate symbol of audacity signed by BOMBERG .

Technical details:

Reference:

CT43ASS.30-1.11

Movement:

Automatic 3 hands, Sellita SW200, 38 hours power reserve

Case:

43mm, stainless steel case

 

Outer ring with CBD leaves pattern

Dial:

Strong Superluminova on the Indica leaf

 

Real organic US hemp inside the dial below the Indica leaf

Crystal:

Sapphire with anti reflective coating

WR:

50m

Strap:

Fabric strap made with US hemp

Buckle:

Stainless steel folding clasp

 

RRP CHF, VAT excl. CHF 1’790

 

Quantity SPECIAL EDITION with limited production

Link:

ClickThru

Social Media:

https://www.facebook.com/bombergofficial

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 13:00:00 CEST | Press release

Global brands including Bosch, Castrol, Coca-Cola Al Ahlia Beverages, and Moët Hennessy take the stage in Barcelona as Kinaxis sets the direction for the next era of supply chain Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat

Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 13:00:00 CEST | Press release

The Danish medtech company's ear-EEG platform can now be placed on the European market, enabling clinicians to record multi-day and multi-night EEG in the patient's home for epilepsy, sleep and other neurophysiological research and care. Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release

New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD)​ TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated

NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 12:00:00 CEST | Press release

Building on NIQ's GeoPurchase capabilities, the new solution extends geographic purchase intelligence into digital-first categories across Europe NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these sig

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 12:00:00 CEST | Press release

Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platformLilly to make a strategic investment in QurCan QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboratio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye